Company profile for Syndax Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, and is currently being evaluated in a...
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, and is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer in combination with exemestane, E2112.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
35 Gatehouse Drive Building D, Floor 3 Waltham, MA 02451
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196834/0/en/Syndax-Announces-Participation-at-the-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/05/3181896/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179405/0/en/Syndax-to-Host-ASH-Investor-Event-in-Person-and-via-Webcast-on-December-8-2025.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179404/0/en/Syndax-Announces-Compelling-Revuforj-revumenib-and-Niktimvo-axatilimab-csfr-Data-Accepted-for-Presentation-at-ASH-2025.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179757/0/en/Syndax-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177238/0/en/Syndax-Announces-Participation-in-November-Investor-Conferences.html

GLOBENEWSWIRE
30 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty